Open Access Full Text Article

Sarcomatoid Renal Cell Carcinoma: Report of a Large Malignant Tumor with a Review of the Literature

Yasaman Naghibzadeh^{1,2}, Arshia Javadizadeh^{1,2}, Farhad Amirian^{2,3}, Mazaher Ramezani^{2,3,*}

ABSTRACT

Introduction: Sarcomatoid renal cell carcinoma is a rare and aggressive kidney tumor characterized by a poor prognosis and distinct microscopic features. Traditional modalities, as opposed to new targeted therapies, are used in treating various patients, yielding controversial but somewhat promising results. Method: A 73-year-old man presented with right flank pain and hematuria. A computed tomography (CT) scan identified a solid mass measuring 62x100 mm in the posterior right kidney with perinephric infiltration. Multiple tumor nodules were noted in the perinephric fat. Additionally, a metastatic mass measuring 21x33 mm was found in the right adrenal gland, along with several metastatic lymph nodes measuring up to 18 mm in the paraaortic, renal hilum, and right retrocrural space. Result: A radical nephrectomy was performed. The cut section of the kidney revealed a firm, homogeneous, gray-yellowish mass measuring 13.5 cm. The pathology report stated, "Renal cell carcinoma, sarcomatoid type, high grade (4/4), invading perirenal fat with a greatest diameter of 13.5 cm and clear surgical and vascular margins." Immunohistochemical staining was positive for CK, Vimentin, and CD10, and negative for EMA, CK7, Desmin, Myogenin, and E-Cadherin. Unfortunately, the patient passed away 25 days later due to complications from lung and cardiac failure. Conclusion: Pathologists and clinicians should be familiar with this rare but aggressive entity to enable earlier diagnosis and treatment. Different treatment modalities should be assessed to improve patient outcomes.

Key words: Renal cell carcinoma, Sarcomatoid, Case report

INTRODUCTION

Renal cell carcinoma (RCC) is one of the most common malignancies of visceral organs in individuals aged 50 to 70^{1,2}. Sarcomatoid RCC (sRCC) represents a transformation of RCC characterized by the presence of spindle-shaped cells, high cellularity, atypia, increased mesenchymal differentiation, and loss of epithelial features. It can occur in all subtypes of RCC. These features are most commonly observed in chromophobe RCC (8.7%) compared to clear cell RCC (5.2%) and papillary RCC (1.9%)^{1,3,4}. Approximately 20% of sRCC cases are associated with metastases to sites such as the lymph nodes, lungs, and liver, significantly reducing the survival rate to less than one year^{5,6}. The most prevalent symptoms of sRCC include abdominal pain and hematuria⁷. sRCC is more commonly diagnosed in males (M/F ratio: 1.3-2/1)^{1,2,5}. This article describes a significant case of sRCC with metastasis to the right adrenal gland, paraaortic lymph nodes, renal hilum, and right retrocrural space in a 73-year-old male.

CASE REPORT

A 73-year-old man was referred on July 16, 2017, due to persistent right flank pain over two months

and hematuria lasting two days. The hematuria was painful and contained blood clots. Symptoms also included nausea, urinary frequency, nocturia, and dribbling. He reported significant weight loss, anorexia, bone pain, dyspnea, and cough. His medical history noted chronic obstructive pulmonary disease (COPD) and cigarette smoking. Both of his nieces had undergone kidney transplants, as mentioned in his family history. During the physical examination, his vital signs were stable, with mild generalized wheezing and right costovertebral angle tenderness observed. A CT scan on July 3 reported moderate left pleural effusion with mild right pleural effusion and pericardial effusion. A solid mass measuring 62x100 mm in the posterior right kidney with perinephric infiltration and multiple tumor nodules in the perinephric fat were visible. Central necrosis in the masses and adhesion to the right superior psoas muscle were present. A metastatic mass measuring 21x33 mm in the right adrenal gland and several metastatic lymph nodes measuring 18 mm in the paraaortic, renal hilum, and right retrocrural space were noted. In the left liver lobe's internal segment, a mass measuring 56x80 mm with peripheral nodular enhancement suggested a cavernous hemangioma, but renal mass

Cite this article : Naghibzadeh Y, Javadizadeh A, Amirian F, Ramezani M. Sarcomatoid Renal Cell Carcinoma: Report of a Large Malignant Tumor with a Review of the Literature. *Biomed. Res. Ther.* 2024; 11(3):6263-6267.

¹Students Research Committee, Kermanshah University of Medical Sciences, Kermanshah, Iran

²Clinical Research Development Center, Imam Reza Hospital, Kermanshah University of Medical Sciences, Kermanshah, Iran

³Molecular Pathology Research Center, Imam Reza Hospital, Kermanshah University of Medical Sciences, Kermanshah, Iran

Correspondence

Mazaher Ramezani, Clinical Research Development Center, Imam Reza Hospital, Kermanshah University of Medical Sciences, Kermanshah, Iran

Molecular Pathology Research Center, Imam Reza Hospital, Kermanshah University of Medical Sciences, Kermanshah, Iran

Email: mazaher_ramezani@yahoo.com

- History
- Received: Oct 24, 2023
- Accepted: Mar 13, 2024
- Published Online: Mar 31, 2024

DOI: 10.15419/bmrat.v11i3.871

Check for updates

Copyright

© Biomedpress. This is an openaccess article distributed under the terms of the Creative Commons Attribution 4.0 International license.



metastasis could not be excluded. MRI with contrast for the hepatic lesion was recommended. No venous thrombosis or bile duct dilation was observed. The spleen, left kidney, left adrenal, and pancreas were unremarkable.

A right radical nephrectomy was performed on July 16 for a metastatic tumor involving the right kidney, aortic and vena cava lymph nodes, with adhesion and invasion into the abdominal wall muscle. The specimen sent to pathology consisted of a kidney tissue piece measuring 15.5x5 cm and several tan-brown separate pieces measuring 9x5x4 cm. The cut section of the kidney revealed a firm, homogeneous, gray-yellowish mass measuring 13.5 cm. The pathologist reported: "Renal cell carcinoma, Sarcomatoid type (Figure 1), high grade (4/4) invading perirenal fat with the largest diameter of 13.5 cm and clear surgical and vascular margins. Immunohistochemical (IHC) staining was positive for CK, Vimentin, and CD10 (Figure 2), and negative for EMA, CK7, Desmin, Myogenin, and E-Cadherin." The patient was assessed by a cardiologist as a case of congestive heart failure and managed accordingly. His ejection fraction was 35%. On the day of the operation, he experienced respiratory distress, and pleural effusion was suggested. His condition gradually deteriorated, and he was intubated. On July 30, 2017, a lung physician evaluated him for lung metastasis and pleural effusion, ordering a spiral lung CT scan. Bilateral pleural effusions with a loculated appearance on the left and passive lung collapse mainly on the right were noted, along with emphysematous changes in both lungs. Thinning of the right lower lobe bronchus and distal obstruction, as well as thickening of the interlobular septa in the left lingual lobe and right lower lobe, suggested carcinomatous lymphangiitis. On August 3, 2017, he was admitted to the ICU, and a bilateral chest tube was placed. The patient was unconscious with a Glasgow Coma Scale (GCS) score of 3-4/15. He required dialysis, but it was not feasible due to his shock state. On August 11, 2017, he suffered a cardiopulmonary arrest and despite resuscitation efforts, he expired 40 minutes later. Written consent for the case report was obtained from the family.

DISCUSSION

Sarcomatoid renal cell carcinoma (sRCC) is a rare dedifferentiation of RCC observed across all subtypes, associated with poor prognosis and aggressive behavior^{6,8}. It exhibits specific histological features including spindle cells, sarcomatoid characteristics (compartments containing fibrous, leiomyomatous,

rhabdoid, osteoid, or chondroid materials), pleomorphism, and high cellularity^{1,5}. sRCC often presents with coagulative necrosis (90%) and, less frequently, with microvascular invasion and rhabdoid features (15%)¹. Macroscopically, sRCC is characterized by necrosis, hemorrhage, large size, and a firm texture with yellowish or gray solid lesions^{1,2}.

The symptoms of sRCC vary at presentation. Common clinical signs include flank pain (51%), hematuria (22-34.7%), weight loss (18-22.6%), fever (6-10.6%), fatigue (15%), night sweats (6-12.6%), and cough or dyspnea (6%). In this patient, symptoms included right flank pain, hematuria, weight loss, nocturia, and bone pain 1,5 .

The epithelial-mesenchymal transition (EMT) in sRCC, a morphological shift between mesenchymal and epithelial cells, facilitates proliferation and metastasis, often resulting in high-stage diagnoses at presentation^{4,5}. Common metastasis sites include the lungs, bones, lymph nodes, and brain¹. In this case, metastases involved the right adrenal gland, paraaortic lymph nodes, renal hilum, right retrocrural space, and carcinomatous lymphangitis in the lungs. It is noteworthy that the WHO and the International Society of Urologic Pathology (ISUP) classify sRCC as a high-grade tumor (grade 4) in the TNM classification system⁸. The high-grade classification of sRCC is often attributed to the absence or interaction of factors like ARID1A and BAP19. These characteristics contribute to a median survival time of less than one year at every stage, compared to non-sarcomatoid RCC^{1,9}. sRCC's incidence varies by gender, being more prevalent in males. Possible reasons for this gender differentiation include smoking habits, the effects of sex hormones, and occupational exposure^{1,5}.

Immunohistochemical markers often found positive in sRCC include AE1/AE4, epithelial membrane antigen, and vimentin, while markers like CK7, actin, desmin, and S-100 are typically negative^{2,7}. In this patient, IHC was positive for CK, vimentin, and CD10, and negative for EMA, CK7, desmin, myogenin, and E-cadherin.

Mutations commonly observed in sRCC include TP53 (42%), VHL (35%), CDKN2A (27%), and NF2 (19%)³.

Therapeutic approaches for sRCC vary. Identification via biopsy and radiography aids in selecting appropriate treatments⁹. However, the absence of specific clinical features or limited sarcomatoid areas may render these diagnostic methods less effective⁹. The recommended treatments include surgery and systemic therapy⁹. In cases with metastasis or




Figure 1: Spindle-shaped cells, high cellularity, atypia, increasing mesenchymal differentiation, and losing epithelial features. Hematoxyline-Eosin stain X100 magnification.

where surgery is not available, systemic therapy using targeted agents and immune checkpoint inhibitors is beneficial⁹. These treatments can restrict tumor growth, with agents like VEGF inhibitors being particularly effective against metastatic RCC⁹. Combining VEGF with Trebananib, an Ang/Tie-2 pathway inhibitor, can enhance the effectiveness of blocking vessel formation¹⁰. Other effective treatments include combinations of sunitinib with gemcitabine or gemcitabine with doxorubicin³.

Immunotherapy, particularly using interferon-alpha (IFN- α) and interleukin-2 (IL-2), or targeting biomarkers like PD-L1, is another recommended treatment approach^{8,11}. Cytoreductive nephrectomy can be attempted, but outcomes are not always favorable⁸. A nephrectomy was performed in our case, but unfortunately, it did not save the patient's life.

CONCLUSION

Sarcomatoid RCC (sRCC) represents a transformation of RCC characterized by spindle-shaped cells, high cellularity, atypia, increasing mesenchymal differentiation, and loss of epithelial features. sRCC is a rare and aggressive kidney tumor associated with a poor prognosis. Metastases to organs such as the lungs and liver are common, resulting in a median survival time of less than a year after diagnosis. Pathologists and clinicians should be familiar with this rare but aggressive entity to enable earlier diagnosis and treatment. Various treatments should be evaluated to enhance patient care.

ABBREVIATIONS

AE1/AE4: Pan-cytokeratin markers, **ARID1A:** ATrich interaction domain 1 A, **BAP1**: BRCA1 associated protein-1, **CDKN2A:** Cyclin-Dependent Kinase Inhibitor 2A, **CK:** Cytokeratin, **CK7:** Cytokeratin 7, **COPD:** Chronic Obstructive Pulmonary Disease, **CT:** Computed Tomography, **EMA:** Epithelial Membrane Antigen, **GCS:** Glasgow Coma Scale, **ICU:** Intensive Care Unit, **IFN-\alpha:** Interferon-alpha, **IL-2:** Interleukin-2, **IHC:** Immunohistochemical, **ISUP:** International Society of Urologic Pathology, **MRI:** Magnetic Resonance Imaging, **NF2:** Neurofibromin 2, **PD-L1:** Programmed Death-Ligand 1, **RCC:** Renal Cell Carcinoma, **sRCC:** Sarcomatoid Renal Cell Carcinoma, **TNM:** Tumor, Node, Metastasis (a staging system), **TP53:** Tumor Protein P53, **VEGF:** Vas-




Figure 2: CD10 positivity. Immunohistochemistry stain X100 magnificaton.

cular Endothelial Growth Factor, VHL: Von Hippel-Lindau gene, WHO: World Health Organization

ACKNOWLEDGMENTS

We thank the Clinical Research Development Center of Imam Reza Hospital for Consultation.

AUTHOR'S CONTRIBUTIONS

All authors significantly contributed to this work, read and approved the final manuscript.

FUNDING

None.

AVAILABILITY OF DATA AND MATERIALS

Data and materials used and/or analyzed during the current study are available from the corresponding author on reasonable request.

ETHICS APPROVAL AND CONSENT TO PARTICIPATE

The article is written according to the orders of ethics committee of KUMS.

CONSENT FOR PUBLICATION

Written informed consent was obtained from the family of the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.

COMPETING INTERESTS

The authors declare that they have no competing interests.

REFERENCES

- Blum KA, Gupta S, Tickoo SK, Chan TA, Russo P, Motzer RJ, et al. Sarcomatoid renal cell carcinoma: biology, natural history and management. Nature Reviews Urology. 2020;17(12):659– 78. PMID: 33051619. Available from: https://doi.org/10.1038/ s41585-020-00382-9.
- Neşiu A, NeamC, Nicolescu CM, Totolici BD, Mureşanu HD, Roşu MC, et al. Sarcomatoid renal cell carcinoma with clear cells and eosinophilia: a case report and short review of the literature. Romanian Journal of Morphology and Embryology. 2021;62(3):835–9. PMID: 35263413. Available from: https: //doi.org/10.47162/RJME.62.3.22.
- Pichler R, Compérat E, Klatte T, Pichler M, Loidl W, Lusuardi L, et al. Renal cell carcinoma with sarcomatoid features: finally new therapeutic hope? Cancers (Basel). 2019;11(3):422.
 PMID: 30934624. Available from: https://doi.org/10.3390/ cancers11030422.
- Miolo G, Ash A, Buonadonna A, Re GL, Torrisi E, Cervo S, et al. Grade 4 unclassified renal cell carcinoma with sarcomatoid

component expressing S-100 protein. A case report with peculiar diagnostic and therapeutic implications. Cancer Biology & Therapy. 2014;15(11):1439–43. PMID: 25482943. Available from: https://doi.org/10.4161/15384047.2014.956642.

- Warli SM, Andy A, Mariedina CT, Nasution R, Kadar DD. A Rare Case of Sarcomatoid Renal Cell Carcinoma in a Young Adult Patient. Research and Reports in Urology. 2022;14:241– 5. PMID: 35734241. Available from: https://doi.org/10.2147/ RRU.S370975.
- Liao X, Abu-Farsakh SH, Zhang D. Sarcomatoid renal cell carcinoma with unusual metastasis to the small intestine manifesting as perforated appendicitis. in vivo. 2019;33(6):2225–8.
- Golshayan AR, George S, Heng DY, Elson P, Wood LS, Mekhail TM, et al. Metastatic sarcomatoid renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. Journal of Clinical Oncology. 2009;27(2):235–41. PMID: 19064974. Available from: https://doi.org/10.1200/JCO.2008. 18.0000.
- Oudad F, Karam R, Tawfiq N, Jouhadi H, Aboutaieb R, Karkouri M. Sarcomatoid Renal Cell Carcinoma, or Renal cell carcinoma with sarcomatoid dedifferentiation: review of literature. Translational Oncology and Therapeutics. 2023;1(1):1–5.
- Liang X, Liu Y, Ran P, Tang M, Xu C, Zhu Y. Sarcomatoid renal cell carcinoma: a case report and literature review. BMC Nephrology. 2018;19(1):84. PMID: 29636020. Available from: https://doi.org/10.1186/s12882-018-0884-7.
- Makhov P, Joshi S, Ghatalia P, Kutikov A, Uzzo RG, Kolenko VM. Resistance to systemic therapies in clear cell renal cell carcinoma: mechanisms and management strategies. Molecular Cancer Therapeutics. 2018;17(7):1355–64. PMID: 29967214. Available from: https://doi.org/10.1158/1535-7163.MCT-17-1299.
- Barata PC, Rini BI. Treatment of renal cell carcinoma: current status and future directions. CA: a Cancer Journal for Clinicians. 2017;67(6):507–24. PMID: 28961310. Available from: https://doi.org/10.3322/caac.21411.